Epigenetics Market worth $783.17 Million by 2019, According to a New Study on ASDReports

Wednesday 8 October 2014, Amsterdam

The global epigenetics market was valued at an estimated $413.24 million in 2014. This market is expected to grow at a CAGR of 13.64% between 2014 and 2019 to reach $783.17 million in 2019.

The epigenetics market is segmented on the basis of products into enzymes; instruments and consumables; kits; and reagents. Each of these market segments is further divided into multiple product segments and sub-segments. The epigenetics enzymes market consists of three subsegments, namely, DNA-modifying enzymes; protein-modifying enzymes; and RNA-modifying enzymes. Of these, the DNA-modifying enzymes segment had the largest share of the epigenetics enzymes market in 2014 and is expected to grow at the highest CAGR between 2014 and 2019. The subsegments of the epigenetics instruments and consumables market are mass spectrometers; next-generation sequencers; qPCRs; sonicators; and other epigenetics instruments & consumables. Of these, the next-generation sequencers segment had the largest share of the epigenetics instruments and consumables market in 2014 and is expected to grow at the highest CAGR between 2014 and 2019.The subsegments of the epigenetics kits segments are bisulfite conversion kits; ChIP- seq kits; RNA sequencing kits; whole genome amplification kits; 5-hmC & 5-mC analysis kits; and other epigenetics kits. Of these, the ChIP- seq kits segment had the largest share in 2014. The whole genome amplification kits segment is expected to grow at the highest CAGR between 2014 and 2019. The epigenetics reagents market consists of six segments, namely, antibodies; buffers; histones; magnetic beads; primers; and other epigenetics reagents. Of these, the antibodies segment had the largest share of the epigenetics reagents market in 2014 and is expected to grow at the highest CAGR between 2014 and 2019.

The research areas included in this report are developmental biology, drug discovery, oncology and other research areas. The oncology research segment had the largest share of the epigenetics market in 2014, whereas the drug discovery segment is expected to grow at the highest CAGR between 2014 and 2019. The geographic segments included in this report are North America, Europe, Asia, and Rest of the World.

Increasing prevalence of cancer will be the most important growth driver for the epigenetics market. Furthermore, increased funding for epigenetics research, along with growing partnerships between biotechnology and pharmaceutical companies for the development of epigenetics-based products, will aid the growth of this market.

Major players in the epigenetics market include Abcam (U.K.), Active Motif (U.S.), Diagenode (Belgium), EMD Millipore (U.S.), Illumina (U.S.), New England Biolabs (U.S.), QIAGEN (Netherlands), Sigma-Aldrich (U.S.), Thermo Fisher Scientific (U.S.), and Zymo Research (U.S.).